Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine | Zendy

Myrna Candelaria | Zendy; Carmen Corrales-Alfaro | Zendy; Olga Gutiérrez | Zendy; José DíazChávez | Zendy; J Labardini-Méndez | Zendy; Silvia Vidal-Millán | Zendy; Luis A. Herrera | Zendy

Open Access

Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine

Author(s) -

Myrna Candelaria,

Carmen Corrales-Alfaro,

Olga Gutiérrez,

José DíazChávez,

J Labardini-Méndez,

Silvia Vidal-Millán,

Luis A. Herrera

Publication year - 2016

Publication title -

chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.539

H-Index - 54

eISSN - 1421-9794

pISSN - 0009-3157

DOI - 10.1159/000445370

Subject(s) - deoxycytidine kinase , cytarabine , myeloid leukemia , deoxycytidine , medicine , oncology , regimen , pharmacology , chemotherapy , gemcitabine

Cytarabine (Ara-C) is the primary drug in different treatment schemas for acute myeloid leukemia (AML) and requires the human equilibrative nucleoside transporter (hENT1) to enter cells. The deoxycytidine kinase (dCK) enzyme limits its activation rate. Therefore, decreased expression levels of these genes may influence the response rate to this drug.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research